Tyton Partners and Ufi Ventures Release Q1 2025 VocTech Market Report: Policy Uncertainty, European Resurgence and the Continued Rise of AI Investment
LONDON, May 22, 2025 (GLOBE NEWSWIRE) -- Tyton Partners, the leading strategy consulting and investment banking firm focused on the education sector, and Ufi Ventures, the UK's specialist investor in vocational technology (VocTech), today released their Q1 2025 VocTech Market Report. The quarterly publication analyses economic, political and investment developments that are shaping the vocational learning and workforce development landscape across the UK, Europe and North America.
The report arrives at a time of profound global uncertainty. Early 2025 has brought renewed inflationary pressure, shifting policy landscapes, and intensifying debate around the implications of artificial intelligence, both as a disruptor and an enabler of economic growth. Meanwhile, labour market fragility, skills shortages and social pressures continue to shape employer and policymaker priorities.
Against this backdrop, Tyton and Ufi's latest report identifies five major developments shaping the VocTech investment and innovation environment:
Key Takeaways
Inevitably, we need to talk about US trade tariffs. The disruption they may represent and the uncertainty of their introduction will weigh heavily on policy and investment decisions in the VocTech sector in the UK and Europe. Caution and delay are the most likely effects.
By contrast, Germany's loosening of governmental spending is likely to improve the outlook for the economic and investment environment and make Europe and the UK look like a reliable and interesting place to deploy capital, particularly relative to the US.
Big AI-related venture rounds in education and the Future of Work continue to be made, predominantly in the US but also – patchily – in Europe.
The UK Curriculum Review is progressing, but the interim report gave little away.
Some organisations are forcing a full-time return to the office to increase productivity. This may, in fact, make them less attractive employers.
Macroeconomic indicators across the UK, US and Eurozone reflect rising inflation and slowing growth. The UK's core inflation reached 3.7% in January, while GDP forecasts were halved in the Spring Statement. Unemployment edged upwards to 4.4% and youth disengagement from education and employment reached nearly one million. Meanwhile, Germany's €500B stimulus package and reform of its 'debt brake' has positioned it—and, by association, Europe—as an increasingly attractive investment environment.
Amid political turbulence, the report also notes significant shifts in defence and green economy priorities, the accelerating role of AI across sectors, and evolving models of work and training. Notably, while HR tech investments declined in the UK, both Europe and the US saw a strong rebound in Q1, with major funding rounds in AI-powered learning, recruitment and workforce management solutions.
Helen Gironi, Director at Ufi Ventures, commented:"With macroeconomic headwinds and geopolitical uncertainty reshaping priorities, it is essential that VocTech investment adapts accordingly. This quarter's report offers insight into the risks and opportunities that lie ahead for building a more inclusive and productive future of work."
Nick Kind, Managing Director at Tyton Partners, added:"AI continues to attract capital at scale, especially in the US—but caution is warranted as political and trade dynamics grow more complex. Our goal is to equip investors, educators and policymakers with the insight needed to navigate this complexity and drive meaningful workforce innovation."
To access the full Q1 2025 VocTech Market Report, visit: https://tytonpartners.com/key-learnings-from-voctech-market-activity-q1-2025/
About Tyton Partners
Tyton Partners is the leading provider of strategy consulting and investment banking services to the global knowledge and information services sector. With offices in Boston and New York City, the firm has an experienced team of bankers and consultants who deliver a unique spectrum of services from mergers and acquisitions and capital markets access to strategy development that helps companies, organizations, and investors navigate the complexities of the education, media, and information markets. Tyton Partners leverages a deep foundation of transactional and advisory experience and an unparalleled level of global relationships to make its clients' aspirations a reality and to catalyze innovation in the sector. Learn more at tytonpartners.com.
About Ufi Ventures
Ufi Ventures is the investment arm of Ufi VocTech Trust. Ufi supports the adoption and deployment of technology to improve skills for work and deliver better outcomes for all. By leveraging its depth of experience Ufi Ventures supports its growing portfolio through access to capital, and its wide expert pool and network. Learn more at www.ufi.co.uk/ventures.
Media ContactZoe Wright-NeilDirector of Marketing and Business Developmentzwrightneil@tytonpartners.comTyton Partners
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
SeekOut Appoints Veteran B2B Executive Bala Vishwanath as Chief Marketing Officer to Lead Talent Acquisition's Agentic AI Revolution
Enterprise Marketing Leader Joins to Accelerate Industry Transformation as Companies Race from AI-Powered to AI-Autonomous Recruiting Bala Vishwanath SEATTLE, June 05, 2025 (GLOBE NEWSWIRE) -- SeekOut, the Agentic AI talent acquisition platform, today announced Bala Vishwanath as Chief Marketing Officer, positioning the company to lead recruiting's most fundamental transformation since the dawn of the internet. This strategic appointment comes as enterprises have an unprecedented opportunity to embrace Agentic AI and gain significant competitive advantages in securing top talent. The talent acquisition industry stands at a critical inflection point. While many organizations celebrate basic AI-powered tools that assist recruiters, a seismic shift to autonomous AI agents is already underway. These agents work continuously, sourcing across platforms, conducting deep research and managing personalized campaigns with superhuman scale and precision. Organizations that embrace this evolution early will gain tremendous competitive advantages in securing exceptional talent. "We're witnessing the emergence of Vertical AI with specialized autonomous agents built for specific functions," said Anoop Gupta, co-founder and CEO of SeekOut. "Just as AI transformed finance and healthcare, it's now redefining talent acquisition. Bala understands how to evangelize category-defining transformations. He'll ensure every enterprise leader grasps a simple truth: Agentic AI isn't coming. It's here, and it's creating incredible opportunities for forward-thinking organizations." SeekOut bridges the transformation gap with two revolutionary approaches. SeekOut Recruit represents the "you do it" solution, empowering internal teams with AI superpowers, including semantic search across one billion profiles and intelligent automation. For organizations ready to leap forward, SeekOut Spot delivers the "we do it" experience through true Agentic AI, where autonomous agents work alongside expert advisors to deliver qualified, interested candidates in 3 to 14 days, versus the industry's 60- to 80-day standard. "Every filled position with exceptional talent becomes a competitive advantage for your organization," said Bala Vishwanath. "SeekOut Spot doesn't just accelerate hiring. It fundamentally breaks the speed-quality paradox that has plagued recruiting forever. When AI agents evaluate thousands of candidates in parallel while human experts ensure nuance and fit, you don't get incremental improvement. You get transformation. My mission is simple: help every talent leader understand the incredible opportunities this transformation creates and how they can lead the way in their industry." With over 25 years leading B2B marketing transformations, including establishing CoreStack as the definitive enterprise cloud governance leader, Vishwanath will spearhead SeekOut's market expansion as enterprises worldwide embrace Agentic AI. About SeekOut SeekOut is the Agentic AI talent acquisition platform transforming how enterprises discover and hire exceptional talent. The company's dual approach includes SeekOut Recruit, the "you do it" AI-powered platform trusted by over 1,000 enterprises, and SeekOut Spot, the "we do it" Agentic AI service where autonomous agents and expert advisors deliver complete hiring outcomes. Founded in 2018, SeekOut has raised $189 million from Tiger Global, Madrona and Mayfield, achieving a $1.2 billion valuation. Learn more at A photo accompanying this announcement is available at CONTACT: Media Contact: Kate Achille The Devon Group for SeekOut kate@
Yahoo
40 minutes ago
- Yahoo
NewAmsterdam Pharma to Host R&D Day on June 11, 2025
NAARDEN, The Netherlands and MIAMI, June 05, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or 'NewAmsterdam' or the 'Company'), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ('CVD') with elevated low-density lipoprotein cholesterol ('LDL-C'), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will host an R&D Day event for analysts and investors on June 11, 2025 beginning at 9:00 a.m. ET in New York City. Please join members of our management team, including: Michael Davidson, M.D., Chief Executive Officer, John Kastelein, M.D., Ph.D., FESC, Founder and Chief Scientific Officer, BJ Jones, Chief Commercial Officer, Ian Somaiya, Chief Financial Officer, and Matthew Philippe, Executive Vice President. A live webcast of the R&D event will be available and those who intend to join virtually can pre-register for the webcast through the link here. The live webcast and supporting presentation materials will be available on the Events section of the Investor Relations page of the NewAmsterdam website at at the time of the live event. An archived replay will be available on the NewAmsterdam website. Please note advanced registration is required for in-person attendance. About ObicetrapibObicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company's Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company's Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL CVOT in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company. About NewAmsterdamNewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage, clinical biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Company ContactMatthew PhilippeP: Media ContactSpectrum Science on behalf of NewAmsterdamJaryd LeadyP: 1-856-803-7855jleady@ Investor ContactPrecision AQ on behalf of NewAmsterdamAustin MurtaghP:
Yahoo
41 minutes ago
- Yahoo
Regulatory Affairs Outsourcing Market Analysis Report 2025: Globalization of Biopharmaceutical and Medical Device Companies Bolster Growth - Trends, Opportunities, and Forecasts 2020-2030
Regulatory Affairs Outsourcing Market Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "Regulatory Affairs Outsourcing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to Regulatory Affairs Outsourcing Market was valued at USD 6.84 Billion in 2024, and is expected to reach USD 11.94 Billion by 2030, rising at a CAGR of 9.73% Market expansion is primarily driven by increased R&D efforts and a rising number of clinical trial applications and product registrations. Additionally, regulatory measures aimed at controlling drug costs are generating economic pressures that encourage life sciences companies to outsource regulatory functions. The COVID-19 pandemic further accelerated this trend, as the urgent development of vaccines underscored the importance of streamlined regulatory processes. As globalization continues, companies entering international markets face a complex web of regulatory standards, prompting greater reliance on external expertise to navigate compliance efficiently. This demand is especially strong in emerging markets where operational costs are lower and regulatory environments are increasingly attractive for Market Drivers Globalization of Biopharmaceutical and Medical Device CompaniesThe expansion of biopharmaceutical and medical device companies into international markets is a major driver behind the growth of regulatory affairs outsourcing. Each new market introduces unique compliance requirements, demanding specialized regulatory knowledge. Outsourcing helps companies manage these challenges efficiently and cost-effectively. Emerging regions such as Asia Pacific, Latin America, and the Middle East & Africa are particularly appealing due to lower development costs, skilled labor availability, and favorable regulatory climates. For instance, infrastructure investments like B. Braun's five new facilities in Malaysia and Flex Ltd.'s site in India reflect the trend of companies expanding regionally while leveraging outsourced regulatory expertise to ensure Market Challenges Data Security and Privacy ConcernsSecurity and privacy of sensitive regulatory information are critical challenges in this market. As outsourcing increases, so does the risk of data breaches and cyberattacks. The growing use of digital platforms - such as electronic Common Technical Document (eCTD) submissions and digital IND safety reporting - amplifies vulnerabilities. Additionally, mergers and acquisitions within the healthcare sector can expose organizations to greater cybersecurity threats due to the volume and sensitivity of exchanged data, posing a significant risk to business continuity and regulatory Market Trends Technological Advancements in Regulatory ProcessesTechnological progress is reshaping regulatory affairs outsourcing, introducing tools that enhance transparency, speed, and collaboration. Regulatory Information Management Systems (RIMS) are streamlining submission tracking and compliance monitoring. Cloud-based platforms enable real-time interaction between clients and service providers, improving operational efficiency. Furthermore, artificial intelligence (AI) and machine learning are being used to automate administrative tasks like data entry and document processing, allowing regulatory professionals to focus on strategic functions. These technologies are optimizing regulatory workflows, making it easier for companies to meet global compliance standards swiftly and accurately. Key Attributes: Report Attribute Details No. of Pages 180 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $6.84 Billion Forecasted Market Value (USD) by 2030 $11.94 Billion Compound Annual Growth Rate 9.7% Regions Covered Global Report Scope: Competitive LandscapeCompany Profiles: Detailed analysis of the major companies present in the Global Regulatory Affairs Outsourcing Market. Accell Clinical Research, LLC. Genpact Ltd. CRITERIUM, INC. Promedica International. WuXi AppTec Co Ltd. Medpace Inc. Charles River Laboratories Inc. ICON plc. Covance, Inc. Parexel International Corporation. Regulatory Affairs Outsourcing Market, By Service: Regulatory Consulting Legal Representation Regulatory Writing & Publishing Product registration & clinical trial applications Regulatory Submissions Regulatory Operations Other services Regulatory Affairs Outsourcing Market, By Category: Pharmaceutical Medical Device Regulatory Affairs Outsourcing Market, By Company Size: Small Companies Medium Companies Large Companies Regulatory Affairs Outsourcing Market, By Indication: Oncology Neurology Cardiology Immunology Other Indications Regulatory Affairs Outsourcing Market, By Product Stage: Preclinical Clinical Premarket Approval Regulatory Affairs Outsourcing Market, By End Use: Medical Device Companies Pharmaceutical Companies Biotechnology Companies Regulatory Affairs Outsourcing Market, By Region: North America United States Canada Mexico Europe France Germany United Kingdom Italy Spain Asia Pacific China India Japan South Korea Australia South America Brazil Argentina Colombia Middle East & Africa South Africa Saudi Arabia UAE For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Regulatory Affairs Outsourcing Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data